Literature DB >> 17929125

Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatologists (2007).

Shumpei Yokota1, Masaaki Mori, Tomoyuki Imagawa, Syuji Takei, Takuji Murata, Minako Tomiita, Yasuhiko Ito, Satoshi Fujikawa.   

Abstract

The Pediatric Standing Committee of the Japan College of Rheumatology, in collaboration with the Pediatric Rheumatology Association of Japan, produced guidance on the diagnosis and treatment for juvenile idiopathic arthritis (JIA) for primary care pediatricians and nonpediatric rheumatologists in Japan. This guidance aims to achieve early diagnosis and treatment for JIA, which is similar to adult rheumatoid arthritis (RA), based on recent progress in rheumatology, and to resolve arthritis at an early stage and improve the prognosis of the affected inflammatory joints. It describes clinical symptoms and laboratory findings characteristic to JIA in order to make early diagnosis and treatment possible, and also serves as a triage of patients who are refractory to the treatment protocol described here and need more aggressive interventions. However, because JIA is a complicated and heterogeneous disease and the optimal treatment approach can be diverse and different patient by patient, these guidelines should be viewed as recommendations and be individualized according to the condition of the patient. Finally, we hope that this guidance will trigger exploration for further information by referring to the textbooks and literature listed at the end of these guidelines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17929125     DOI: 10.1007/s10165-007-0625-4

Source DB:  PubMed          Journal:  Mod Rheumatol        ISSN: 1439-7595            Impact factor:   3.023


  4 in total

1.  Chronic noninfectious uveitis associated with Vogt-Koyanagi-Harada disease treated with low-dose weekly systemic methotrexate.

Authors:  Yukiko Kondo; Ken Fukuda; Katsuyoshi Suzuki; Teruo Nishida
Journal:  Jpn J Ophthalmol       Date:  2011-10-26       Impact factor: 2.447

2.  Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.

Authors:  Tomoyuki Imagawa; Syuji Takei; Hiroaki Umebayashi; Kenichi Yamaguchi; Yasuhiko Itoh; Toshinao Kawai; Naomi Iwata; Takuji Murata; Ikuo Okafuji; Mari Miyoshi; Yasuhiro Onoe; Yoshifumi Kawano; Noriko Kinjo; Masaaki Mori; Neelufar Mozaffarian; Hartmut Kupper; Sourav Santra; Gina Patel; Shinichi Kawai; Shumpei Yokota
Journal:  Clin Rheumatol       Date:  2012-10-02       Impact factor: 2.980

3.  Progressive Pseudorheumatoid Dysplasia Misdiagnosed as Seronegative Juvenile Idiopathic Arthritis.

Authors:  Ozgur Taspinar; Fatih Kelesoglu; Yasar Keskin; Murat Uludag
Journal:  Ethiop J Health Sci       Date:  2016-07

4.  Biologic Disease-Modifying and Other Anti-Rheumatic Drugs Use in Patients with Moderate-to-Severe Juvenile Idiopathic Arthritis Based on a Japanese Nationwide Claims Database.

Authors:  Takeo Hata; Atsushi Hirata; Ryosuke Ota; Keiko Hosohata; Masami Nishihara; Masashi Neo; Takahiro Katsumata
Journal:  Ther Clin Risk Manag       Date:  2022-08-24       Impact factor: 2.755

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.